GO:0038164 thrombopoietin receptor activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0038164 thrombopoietin receptor activity is the molecular function of binding the glycoprotein thrombopoietin (THPO) and transmitting its signal across the membrane to initiate changes in cell activity.
• The receptor is encoded by MPL (myeloproliferative leukemia virus oncogene), a member of the hematopoietic cytokine receptor superfamily.
• The thrombopoietin-MPL complex structure has been solved, revealing a 2:2 ligand-receptor architecture that provides a blueprint for engineering biased hematopoietic responses.
• Activating mutations in MPL, such as MPL W515L/K, are driver events in myeloproliferative neoplasms including essential thrombocythemia and primary myelofibrosis.
• Loss-of-function MPL mutations cause congenital amegakaryocytic thrombocytopenia, highlighting the receptor's essential role in megakaryopoiesis and platelet production.
• Thrombopoietin receptor agonists are clinically approved for immune thrombocytopenia and are being explored for hematopoietic stem cell expansion.
Description
Thrombopoietin receptor activity (GO:0038164) is a molecular function defined as combining with the glycoprotein thrombopoietin and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity. This activity is mediated by the MPL protein, the receptor for thrombopoietin (THPO), which is a key regulator of megakaryopoiesis and platelet production. The receptor belongs to the hematopoietic cytokine receptor superfamily and signals through the JAK-STAT pathway to promote proliferation, differentiation, and survival of hematopoietic cells. The thrombopoietin-MPL signaling axis is essential for maintaining hematopoietic stem cell quiescence and self-renewal, as well as for the production of platelets from megakaryocytes. The recent determination of the thrombopoietin-MPL complex structure has provided a molecular blueprint for understanding how ligand binding induces receptor dimerization and activation, with implications for designing biased therapeutics. Dysregulation of thrombopoietin receptor activity is directly linked to human disease. Activating mutations in MPL are driver mutations in myeloproliferative neoplasms, while loss-of-function mutations cause congenital amegakaryocytic thrombocytopenia. Understanding this receptor's function is therefore critical for both basic hematopoiesis research and clinical development of thrombopoietin receptor agonists.
thrombopoietin receptor activity At A Glance
| GO ID | GO:0038164 |
|---|---|
| GO term | thrombopoietin receptor activity |
| Ontology | molecular_function |
| Synonym | None |
| Definition | Combining with the glycoprotein thrombopoietin and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity. |
| Major function | Binding thrombopoietin and initiating intracellular signaling to regulate megakaryopoiesis, platelet production, and hematopoietic stem cell maintenance. |
| Gene encoding receptor | MPL (myeloproliferative leukemia virus oncogene) |
| Ligand | Thrombopoietin (THPO) |
| Pathway | JAK-STAT signaling, PI3K-AKT, MAPK |
What Is GO:0038164?
Thrombopoietin receptor activity (GO:0038164) is the molecular function by which a receptor protein binds the glycoprotein hormone thrombopoietin (THPO) and, upon binding, transmits a signal across the cell membrane to initiate a change in cellular activity. This activity is attributed to the MPL protein, which acts as the primary receptor for thrombopoietin and mediates signaling events that regulate platelet production, megakaryocyte development, and hematopoietic stem cell maintenance.
Why Is thrombopoietin receptor activity Important in Cell Biology?
Thrombopoietin receptor activity is essential for normal hematopoiesis, particularly megakaryopoiesis and platelet production, and for maintaining hematopoietic stem cell function. Its clinical importance is underscored by the fact that mutations in MPL are directly implicated in myeloproliferative neoplasms and congenital amegakaryocytic thrombocytopenia. Furthermore, thrombopoietin receptor agonists have become standard therapies for immune thrombocytopenia and are being investigated for stem cell expansion applications.
• Essential for megakaryocyte differentiation and platelet production.
• Regulates hematopoietic stem cell quiescence, self-renewal, and engraftment.
• Activating mutations (e.g., MPL W515L/K) are driver mutations in essential thrombocythemia and primary myelofibrosis.
• Loss-of-function mutations cause congenital amegakaryocytic thrombocytopenia.
• Target of thrombopoietin receptor agonists used to treat immune thrombocytopenia.
• Critical for chemically defined cytokine-free expansion of human hematopoietic stem cells.
• Serves as a structural blueprint for engineering biased receptor agonists.
• Involved in myeloproliferative neoplasm pathogenesis alongside JAK2 and CALR mutations.
Molecular Mechanism of thrombopoietin receptor activity
Ligand Binding and Receptor Dimerization
In simple terms: Thrombopoietin binds to the MPL receptor on the cell surface, causing two receptor molecules to come together.
Thrombopoietin (THPO) is the primary ligand for the MPL receptor. The recently solved structure of the thrombopoietin-MPL complex reveals a 2:2 ligand-receptor architecture, where two thrombopoietin molecules bind two MPL receptors, inducing receptor dimerization. This dimerization is the critical first step in receptor activation and is required for transmitting the signal across the membrane.
Conformational Change and JAK Activation
In simple terms: When the receptors pair up, they activate JAK enzymes inside the cell.
Upon ligand-induced dimerization, MPL undergoes conformational changes that bring associated JAK kinases into close proximity, enabling their trans-phosphorylation and activation. Activated JAKs then phosphorylate tyrosine residues on the MPL cytoplasmic domain, creating docking sites for downstream signaling molecules.
Downstream Signaling Cascades
In simple terms: The activated receptor turns on multiple signaling pathways that tell the cell to grow and divide.
Phosphorylated MPL recruits and activates STAT proteins (particularly STAT3 and STAT5), which translocate to the nucleus to regulate gene expression. Additionally, MPL signaling activates the PI3K-AKT and MAPK pathways, promoting cell proliferation, survival, and differentiation. These pathways collectively drive megakaryopoiesis and platelet production.
Regulation by Negative Feedback
In simple terms: The cell has ways to shut down the signal to prevent overgrowth.
MPL signaling is negatively regulated by phosphatases such as SHP1 and by suppressor of cytokine signaling (SOCS) proteins, which attenuate JAK-STAT signaling. Additionally, receptor internalization and degradation contribute to signal termination. Dysregulation of these negative feedback mechanisms can lead to constitutive receptor activation, as seen in myeloproliferative neoplasms.
Key Genes Involved in GO:0038164 thrombopoietin receptor activity
The following genes and proteins are central to thrombopoietin receptor activity and its downstream signaling.
| Gene | Major Role | Research Relevance |
|---|---|---|
| MPL | Encodes the thrombopoietin receptor; binds THPO and initiates signaling | Driver mutations in myeloproliferative neoplasms; target for receptor agonists |
| THPO | Ligand for MPL; activates receptor signaling | Regulates platelet production; therapeutic use in thrombocytopenia |
| JAK2 | Kinase activated by MPL; phosphorylates STATs | JAK2 V617F mutation is a major driver in MPNs |
| STAT3 | Transcription factor downstream of MPL; regulates gene expression | Mediates proliferative and survival signals |
| STAT5 | Transcription factor downstream of MPL; regulates gene expression | Mediates megakaryocytic differentiation signals |
| CALR | Calreticulin; mutated in MPNs; interacts with MPL | CALR mutations activate MPL in MPNs |
| SHP1 | Phosphatase that negatively regulates MPL signaling | Modulates signal duration and intensity |
| SOCS proteins | Negative regulators of JAK-STAT signaling | Feedback inhibition of MPL signaling |
| PI3K | Lipid kinase activated by MPL; promotes survival | Downstream effector of MPL signaling |
| AKT | Serine/threonine kinase downstream of PI3K | Promotes cell survival and proliferation |
| MAPK | Mitogen-activated protein kinase pathway | Regulates proliferation and differentiation |
| GATA1 | Transcription factor essential for megakaryopoiesis | Cooperates with MPL signaling for platelet production |
| NF-E2 | Transcription factor regulating platelet gene expression | Downstream target of MPL signaling |
| FOG1 | Co-factor for GATA1 in megakaryopoiesis | Modulates megakaryocytic differentiation |
| TPO receptor agonists | Small molecules or peptides activating MPL | Therapeutic agents for immune thrombocytopenia |
| Eltrombopag | Small molecule thrombopoietin receptor agonist | Clinically approved for ITP and aplastic anemia |
| Romiplostim | Peptide thrombopoietin receptor agonist | Clinically approved for ITP |
How Is thrombopoietin receptor activity Regulated?
Thrombopoietin receptor activity is tightly regulated at multiple levels. Ligand availability is controlled by thrombopoietin production in the liver and its clearance by platelets and megakaryocytes. At the receptor level, MPL surface expression is regulated by internalization and degradation following activation. Negative feedback mechanisms involving SHP1 and SOCS proteins attenuate JAK-STAT signaling to prevent excessive proliferation. Additionally, CALR mutations in myeloproliferative neoplasms can lead to constitutive MPL activation, demonstrating the importance of proper regulation.
thrombopoietin receptor activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| MPL | Essential thrombocythemia, primary myelofibrosis | MPL W515L knock-in mouse model |
| MPL | Congenital amegakaryocytic thrombocytopenia | MPL knockout mouse or patient-derived iPSCs |
| CALR | Myeloproliferative neoplasms | CALR mutant knock-in mouse |
| JAK2 | Polycythemia vera, essential thrombocythemia | JAK2 V617F knock-in mouse |
| THPO | Thrombocytopenia | THPO knockout mouse |
Myeloproliferative Neoplasms
Activating mutations in MPL, most commonly W515L or W515K, are driver mutations in essential thrombocythemia and primary myelofibrosis. These mutations lead to constitutive activation of the receptor in the absence of thrombopoietin, resulting in uncontrolled megakaryopoiesis and platelet overproduction. MPL mutations are found in approximately 5-10% of patients with essential thrombocythemia and primary myelofibrosis, and they define a specific molecular subtype of these diseases. The discovery of CALR mutations has further highlighted the central role of MPL signaling in MPN pathogenesis, as mutant CALR activates MPL.
Congenital Amegakaryocytic Thrombocytopenia
Loss-of-function mutations in MPL cause congenital amegakaryocytic thrombocytopenia (CAMT), a rare inherited disorder characterized by severe thrombocytopenia and absent or reduced megakaryocytes in the bone marrow. Patients with CAMT typically present with bleeding symptoms in infancy and may progress to bone marrow failure. This condition underscores the essential role of thrombopoietin receptor activity in normal platelet production.
Immune Thrombocytopenia and Therapeutic Applications
Thrombopoietin receptor agonists, including romiplostim and eltrombopag, are effective treatments for immune thrombocytopenia (ITP) and have been investigated for other thrombocytopenic conditions. These agents activate MPL signaling to stimulate platelet production. Additionally, thrombopoietin receptor activation is being explored for ex vivo expansion of hematopoietic stem cells for transplantation.
From thrombopoietin receptor activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does MPL loss affect megakaryopoiesis? | MPL knockout mouse or human iPSC-derived megakaryocytes |
| How does MPL W515L mutation drive MPN? | MPL W515L knock-in mouse model |
| Can mutant MPL be targeted therapeutically? | Point mutation knock-in cell lines and patient-derived cells |
| What is the role of MPL in HSC expansion? | Tagged MPL knock-in for imaging and tracking |
| Does MPL overexpression affect platelet production? | MPL overexpression transgenic mouse |
| How does CALR mutation activate MPL? | CALR mutant knock-in with MPL reporter |
How to Study the thrombopoietin receptor activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Flow cytometry | MPL surface expression and phospho-STAT levels | Assessing receptor activation in response to THPO |
| Cryo-EM | Three-dimensional structure of THPO-MPL complex | Understanding ligand-receptor interactions |
| Surface plasmon resonance | Binding affinity between THPO and MPL variants | Characterizing mutant receptors |
| CRISPR knockout screens | Genes required for MPL signaling | Identifying novel regulators of megakaryopoiesis |
| Mouse models | Platelet counts and megakaryocyte numbers | Studying MPN pathogenesis |
| Western blot | Phosphorylation of JAK2, STAT3, STAT5 | Measuring pathway activation |
| Colony-forming assays | Megakaryocyte colony formation | Assessing differentiation potential |
| RNA-seq | Transcriptional changes downstream of MPL | Identifying target genes of MPL signaling |
Flow Cytometry and Phospho-STAT Analysis
Flow cytometry can be used to measure MPL surface expression and phosphorylation of downstream STAT proteins in response to thrombopoietin stimulation. This method allows quantification of receptor activation at the single-cell level and is useful for assessing the effects of mutations or therapeutic agents.
Structural Biology and Biophysical Assays
The structure of the thrombopoietin-MPL complex has been determined using cryo-electron microscopy and X-ray crystallography, revealing the 2:2 ligand-receptor architecture. Surface plasmon resonance and isothermal titration calorimetry can measure binding affinities between thrombopoietin and MPL variants.
CRISPR Screening and Functional Genomics
CRISPR knockout screens can identify genes that modulate thrombopoietin receptor signaling and megakaryopoiesis. These screens are particularly useful for discovering novel regulators of MPL signaling and for identifying synthetic lethal interactions in MPL-mutant cells.
In Vivo Models and Platelet Count Monitoring
Mouse models with MPL mutations or knockouts are essential for studying thrombopoietin receptor activity in vivo. Platelet counts, megakaryocyte morphology, and hematopoietic stem cell function can be assessed to evaluate the physiological consequences of altered MPL signaling.
How CRISPR Can Be Used to Study GO:0038164 thrombopoietin receptor activity
Knockout
CRISPR knockout of MPL can be used to eliminate thrombopoietin receptor activity and study its role in megakaryopoiesis and hematopoietic stem cell function. MPL knockout cell lines and mouse models recapitulate features of congenital amegakaryocytic thrombocytopenia and are valuable for validating the specificity of receptor agonists.
Point Mutation
CRISPR point mutation knock-in can introduce clinically relevant MPL mutations such as W515L or W515K to model myeloproliferative neoplasms. These models are essential for studying constitutive receptor activation and for testing targeted therapies.
Knock-in
Knock-in of tagged MPL (e.g., fluorescent or epitope tags) allows real-time tracking of receptor localization, trafficking, and interaction with downstream signaling molecules. This approach is valuable for understanding the spatiotemporal dynamics of thrombopoietin receptor activity.
Overexpression
Overexpression of wild-type or mutant MPL can be achieved via CRISPR-mediated knock-in of a strong promoter or lentiviral transduction. Overexpression models are useful for studying the effects of increased receptor dosage on platelet production and for screening receptor agonists.
How EDITGENE Supports thrombopoietin receptor activity Research
Researchers studying thrombopoietin receptor activity-related genes often need to determine whether a candidate gene is causally involved in megakaryopoiesis, platelet production, or myeloproliferative disease. EDITGENE provides comprehensive CRISPR-based services to generate precisely engineered cell models for such investigations.
Contact EDITGENE today to design your custom CRISPR model for thrombopoietin receptor activity research.
Frequently Asked Questions About thrombopoietin receptor activity
What is thrombopoietin receptor activity?
Thrombopoietin receptor activity (GO:0038164) is the molecular function of binding the glycoprotein thrombopoietin and transmitting a signal across the cell membrane to initiate changes in cell activity, primarily mediated by the MPL receptor.
What genes are involved in thrombopoietin receptor activity?
The primary gene is MPL, which encodes the receptor. Downstream signaling involves JAK2, STAT3, STAT5, PI3K, AKT, and MAPK. The ligand is encoded by THPO.
What diseases are associated with MPL mutations?
Activating MPL mutations cause myeloproliferative neoplasms such as essential thrombocythemia and primary myelofibrosis, while loss-of-function mutations cause congenital amegakaryocytic thrombocytopenia.
How is thrombopoietin receptor activity measured?
It can be measured by flow cytometry for phospho-STAT levels, Western blot for JAK2/STAT phosphorylation, or by assessing platelet counts in vivo.
What are thrombopoietin receptor agonists?
Thrombopoietin receptor agonists are drugs that activate MPL signaling to stimulate platelet production. Examples include romiplostim and eltrombopag, used to treat immune thrombocytopenia.
What is the structure of the thrombopoietin-MPL complex?
The complex has a 2:2 architecture, with two thrombopoietin molecules binding two MPL receptors, as revealed by recent structural studies.
How do CRISPR knockouts help study thrombopoietin receptor activity?
CRISPR knockouts of MPL or downstream genes eliminate receptor signaling, allowing researchers to study its role in megakaryopoiesis and hematopoietic stem cell function.
Can thrombopoietin receptor activity be targeted for therapy?
Yes, thrombopoietin receptor agonists are already used clinically for immune thrombocytopenia, and antagonists are being explored for myeloproliferative neoplasms.
What is the role of CALR in thrombopoietin receptor signaling?
Mutant CALR can activate MPL signaling in myeloproliferative neoplasms, contributing to disease pathogenesis.
How does thrombopoietin receptor activity affect hematopoietic stem cells?
MPL signaling is essential for maintaining hematopoietic stem cell quiescence and self-renewal, and its activation is used for ex vivo stem cell expansion.
Conclusion
Thrombopoietin receptor activity (GO:0038164) is a critical molecular function that governs megakaryopoiesis, platelet production, and hematopoietic stem cell maintenance. The MPL receptor and its ligand thrombopoietin are central to these processes, and their dysregulation leads to hematological disorders including myeloproliferative neoplasms and congenital amegakaryocytic thrombocytopenia. The recent structural characterization of the thrombopoietin-MPL complex has provided a blueprint for developing biased receptor agonists and antagonists. Ongoing research using CRISPR-based models, structural biology, and functional genomics continues to unravel the complexities of thrombopoietin receptor signaling. These efforts are expected to yield new therapeutic strategies for thrombocytopenia, myeloproliferative neoplasms, and hematopoietic stem cell transplantation.
References
- 1. Guglielmelli P et al.. 2021. The MPL mutation.. Int Rev Cell Mol Biol 365:163-178 PMID: 34756243
- 2. Tsutsumi N et al.. 2023. Structure of the thrombopoietin-MPL receptor complex is a blueprint for biasing hematopoiesis.. Cell 186(19):4189-4203.e22 PMID: 37633268
- 3. Basciano PA et al.. 2012. Thrombopoietin-receptor agonists.. Curr Opin Hematol 19(5):392-8 PMID: 22872157
- 4. Sakurai M et al.. 2023. Chemically defined cytokine-free expansion of human haematopoietic stem cells.. Nature 615(7950):127-133 PMID: 36813966
- 5. Plo I et al.. 2026. Myeloproliferative Neoplasms.. N Engl J Med 395(8):788-802 PMID: 42617115
- 6. Klampfl T et al.. 2013. Somatic mutations of calreticulin in myeloproliferative neoplasms.. N Engl J Med 369(25):2379-90 PMID: 24325356
- 7. Wendling F et al.. 1998. Thrombopoietin and its receptor.. Eur Cytokine Netw 9(3):221-31 PMID: 9831170
- 8. Vainchenker W et al.. 2017. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms.. Blood 129(6):667-679 PMID: 28028029
